Eslicarbazepine Acetate

Paul L. McCormack

doi:10.2165/0023210-200923010-00005

Eslicarbazepine Acetate

2009-01-01

43

PRE

AI

DOI：10.2165/0023210-200923010-00005

原文链接

原文求助

摘要

En 中文

Eslicarbazepine acetate, a prodrug of eslicarbazepine (S-licarbazepine), is a novel, voltage-gated sodium channel antagonist under development for the adjunctive treatment of adult patients experiencing treatment-refractory partial-onset seizures. In phase III trials, eslicarbazepine acetate 800 and 1200 mg once daily significantly reduced seizure frequency compared with placebo over 12 weeks of maintenance treatment in adults experiencing partial-onset seizures who were taking 1-3 concomitant antiepileptic drugs. During long-term, open-label treatment for up to 1 year, eslicarbazepine acetate at a median dosage of 800 mg once daily produced sustained reductions from baseline in seizure frequency. Long-term treatment with eslicarbazepine acetate significantly improved from baseline health-related quality of life as assessed by the Quality-of-Life in Epilepsy Inventory-31 instrument. Similarly, eslicarbazepine acetate significantly reduced depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale. Eslicarbazepine acetate was generally well tolerated in clinical trials. The majority of treatment-emergent adverse events were of mild to moderate severity and most occurred early in treatment.

Keyword:

STEADY-STATE PHARMACOKINETICS

BIA 2-093

HEALTHY-SUBJECTS

BIA-2-093

SEIZURES

ANTICONVULSANT

CARBAMAZEPINE

HIPPOCAMPUS

IMPAIRMENT

PROFILE

Eslicarbazepine Acetate

摘要

AI总结

期刊

机构

引用论文